These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
201 related items for PubMed ID: 16630177
1. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177 [Abstract] [Full Text] [Related]
3. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Cancer; 2006 May 01; 106(9):2005-11. PubMed ID: 16565971 [Abstract] [Full Text] [Related]
4. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM. Cancer; 2003 Aug 15; 98(4):758-64. PubMed ID: 12910520 [Abstract] [Full Text] [Related]
5. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R. Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155 [Abstract] [Full Text] [Related]
14. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK. Pathol Res Pract; 2007 Feb 01; 203(3):127-34. PubMed ID: 17298867 [Abstract] [Full Text] [Related]
15. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Mayorga ME, Sanchis D, Perez de Santos AM, Velasco A, Dolcet X, Casanova JM, Baradad M, Egido R, Pallares J, Espurz N, Benitez D, Mila J, Malvehy J, Castel T, Comella JX, Matias-Guiu X, Vilella R, Marti RM. Melanoma Res; 2006 Apr 01; 16(2):127-35. PubMed ID: 16567968 [Abstract] [Full Text] [Related]
18. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S, Israel Glivec in Solid Tumors Study Group. Endocr Relat Cancer; 2006 Jun 01; 13(2):535-40. PubMed ID: 16728580 [Abstract] [Full Text] [Related]
19. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y. In Vivo; 2003 Jun 01; 17(3):255-8. PubMed ID: 12929576 [Abstract] [Full Text] [Related]
20. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, Söder O, Jahnukainen K. Int J Androl; 2007 Aug 01; 30(4):366-76; discussion 376. PubMed ID: 17705809 [Abstract] [Full Text] [Related] Page: [Next] [New Search]